No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MDRX Veradigm
- 9.850
- -0.130-1.30%
15min DelayClose Jul 11 16:00 ET
- 9.850
- 0.0000.00%
Post 16:01 ET
1.06BMarket Cap24.02P/E (TTM)
9.950High9.660Low1.21MVolume9.660Open9.980Pre Close11.88MTurnover1.78%Turnover Ratio10.15P/E (Static)107.64MShares14.09052wk High0.90P/B669.74MFloat Cap5.01052wk Low--Dividend TTM67.99MShs Float36.176Historical High--Div YieldTTM2.91%Amplitude0.646Historical Low9.839Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Black Book Ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solutions Vendor in 2024
Veradigm(OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research, a healthcare-centric market research and public opinion research and consulting company, rated Veradigm Payer Analytics the overall number one provider of payer analytics solutions for health plans.
Veradigm Payerpath Rated Highest in Client Satisfaction
For the third consecutive year, the comprehensive set of solutions has been rated the overall #1 provider for small physician practice clearinghouse servicesCHICAGO--(BUSINESS WIRE)--Veradigm(OTCMKTS:
Veradigm Is Maintained at Buy by TD Cowen
Veradigm Is Maintained at Buy by TD Cowen
Express News | TD Cowen Maintains Buy on Veradigm, Lowers Price Target to $15
Veradigm Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/28/2024 81.25% TD Cowen $26 → $15 Maintains Buy 03/19/2024 20.84% Deutsche Bank $15 → $10 Downgrades Bu
Express News | Veradigm - Does Not Plan to Make Any Permanent Executive Appointments While Separately Announced Exploration of Strategic Alternatives Is in Process
Comments
Veradigm's promising ROCE trend and its capacity to yield higher returns on less capital is noteworthy. Despite the stock's five-year decline, these trends may warrant further investigation.
Returns At Veradigm (NASDAQ:MDRX) Are On The Way UpThe acquisition is a major chance for Veradigm to broaden its revenue services and utilize more capabilities, says Brian Hall, CEO of Koha Health, seeing it as an opportunity to gain more resources for their client's financial triumph and upgraded patient experience.
Though Veradigm seems undervalued, the pessimistic forecast implies notable risk, raising doubts about intensifying MDRX portfolio exposure. Despite present undervaluation, potential investors considering an entry now must assess negative future growth predictions.
$Veradigm(MDRX.US$ reports earnings for the last 3 months and a full year on February 25th. after recently pulling back I feel like this talk is at a good price point to make an entry and also try to front run the earnings call strategy groups who usually only seem to look a week ahead. this was a position I wanted to enter before I noticed this scenario so it works out well. having any kind of telemedicine in your portfolio right now is a good thing I think...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg